相关实验视频
Updated: Jul 8, 2025
16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
35.3K
个性化身体康复计划的耐受性在患者依赖于因诺托普的支持与终端阶段慢性心力衰竭的患者
M A Bortsova1, E A Demchenko1, P A Fedotov1
1Almazov National Medical Research Center, St-Petersburg.
Kardiologiia
|December 13, 2023
概括
个性化身体康复计划是安全的,并且对于需要内支持的末期慢性心力衰竭 (CHF) 患者来说是可以容忍的. 这种方法不会增加不良事件,使其成为改善患者结果的可行选择.
科学领域:
- 心脏病学 心脏病学
- 康复医学 康复医学 康复医学
- 运动生理学 运动生理学
背景情况:
- 末期慢性心力衰竭 (CHF) 患者通常需要内支持 (例如,多布他胺,多巴胺).
- 在这个弱势群体中,身体康复计划 (PRP) 的作用仍在调查中.
- 评估PRP的安全性和耐受性对于优化CHF管理至关重要.
研究的目的:
- 评估个性化身体康复计划 (PRP) 的耐受性.
- 评估因诺托普依赖的末期慢性心力衰竭 (CHF) 患者的安全性和不良事件 (AEs).
- 为了确定是否持续的无otropic 支持违反了PRP.
主要方法:
- 对120名男性 (18-65岁) 进行前性随机研究,射出分数≤30%.
- 第1组 (40名患者):内支持+PRP;第2组 (40名患者):内支持,没有PRP;第3组 (40名患者):没有内支持+PRP.
- PRP持续时间:6个月;评估运动强度,SPO2和乳酸水平.
主要成果:
- 第1组和第3组 (PRP组) 在没有危及生命的AEs的课程中参加了>80%.
- 在PRP组之间进行比较的运动强度和博格度量得分 (p>0.05).
- 在运动期间,SpO2没有显著下降 (<93%);在PRP组中,乳酸水平仍然可控.
结论:
- 个性化6个月PRP在依赖异基的末期CHF患者中耐受良好,符合安全标准.
- 在这个群体中,PRP不会增加与CHF或康复相关的副作用.
- 如果没有运动不耐受或严重的AEs,那么内托普支持 (dobutamine/dopamine) 不是PRP的禁忌.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:22Heart Failure Drugs: Diuretics
395
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
395
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K